Contemporary Oncology
eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
4/2025
vol. 29
 
Share:
Send email
Share:
Original paper

Cancer-associated thromboses in non-small cell lung cancer patients with epidermal growth factor receptor mutation

Yosuke Maezawa
1
,
Manato Taguchi
2, 3
,
Takeshi Kawakami
2, 3
,
Toshihide Inui
3, 4
,
Takeshi Numata
5
,
Toshihiro Shiozawa
3
,
Kunihiko Miyazaki
6
,
Ryota Nakamura
5
,
Takeo Endo
5
,
Tohru Sakamoto
4
,
Hiroaki Satoh
1
,
Nobuyuki Hizawa
3

  1. Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba, Mito, Japan
  2. Division of Respiratory Medicine, Kobari General Hospital, Noda, Japan
  3. Division of Respiratory Medicine, Faculty of Medicine, University of Tsukuba,Tsukuba, Japan
  4. Division of Respiratory Medicine, Tsukuba Memorial Hospital, Tsukuba, Japan
  5. Departments of Respiratory Medicine and Surgery, National Hospital Organization Mito Medical Center, Ibarakimachi, Japan
  6. Division of Respiratory Medicine, Ryugasaki Saiseikai Hospital, Ryugasaki, Japan
Contemp Oncol (Pozn) 2025; 29 (4): 347–353
DOI: https://doi.org/10.5114/wo.2025.155693
Online publish date: 2025/10/30
Article file
- Cancer-associated.pdf  [0.10 MB]
Get citation
 
PlumX metrics:
 
1. Chew TW, Gau CS, Wen YW, Shen LJ, Mullins CD, Hsiao FY. Epidemiology, clinical profile and treatment patterns of venous thromboembolism in cancer patients in Taiwan: a population-based study. BMC Cancer 2015; 15: 298.
2. Pavlovic D, Niciforovic D, Markovic M, Papic D. Cancer-associated thrombosis: epidemiology, pathophysiological mechanisms, treatment, and risk assessment. Clin Med Insights Oncol 2023; 17: 11795549231220297.
3. Mahajan A, Brunson A, Adesina O, Keegan THM, Wun T. The incidence of cancer-associated thrombosis is increasing over time. Blood Adv 2022; 6: 307-320.
4. Jiménez-Fonseca P, Gallardo E, Arranz Arija F, et al. Consensus on prevention and treatment of cancer-associated thrombosis (CAT) in controversial clinical situations with low levels of evidence. Eur J Intern Med 2022; 100: 33-45.
5. Noble S, Pasi J. Epidemiology and pathophysiology of cancer-associated thrombosis.　Br J Cancer 2010; 102 Suppl 1: S2-9.
6. Sevestre MA, Soudet S. Epidemiology and risk factors for cancer-associated thrombosis. J Med Vasc 2020; 45: 6S3-6S7.
7. Eichinger S. Cancer associated thrombosis: risk factors and outcomes. Thromb Res 2016; 140: S12-S17.
8. Connolly GC, Francis CW. Cancer-associated thrombosis. Hematology Am Soc Hematol Educ Program 2013; 2013: 684-691.
9. Donnellan E, Kevane B, Bird BR, Ainle FN. Cancer and venous thromboembolic disease: from molecular mechanisms to clinical management. Curr Oncol 2014; 21: 134-143.
10. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 2016; 37: 2768-2801.
11. Navi BB, Reiner AS, Kamel H, Iadecola C, Okin PM, Elkind MSV, et al. Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol 2017; 70: 926-938.
12. Dowell JE. Epidermal growth factor receptor mutations in non-small cell lung cancer: a basic science discovery with immediate clinical impact. Am J Med Sci 2006; 331: 139-149.
13. Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 2018; 378: 113-125.
14. Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med 2020; 382: 41-50.
15. Enewold L, Thomas A. Real-world patterns of EGFR testing and treatment with erlotinib for non-small cell lung cancer in the United States. PLoS One 2016; 11: e0156728.
16. Chang WT, Lin HW, Chang TC, Lin SH, Li YH. Assessment of tyrosine kinase inhibitors and survival and cardiovascular outcomes of patients with non-small cell lung cancer in Taiwan. JAMA Netw Open 2023; 6: e2313824.
17. Taguchi M, Kawakami T, Hasegawa S, Okauchi S, Ohara G, Satoh H, et al. EGFR mutated non-small cell lung cancer complicated by cancer associated ischemic stroke. Maedica (Bucur) 2023; 18: 515-518.
18. Masubuchi H, Maeno T, Uchida M, Kono S, Suzuki M, Takemura M, et al. A case of Trousseau syndrome caused by pulmonary adenocarcinoma that was controlled for one year and 10 months with thrombosis treatment using an EGFR tyrosine kinase inhibitor and chemotherapy. Respir Med Case Rep 2015; 15: 101-105.
19. Wang Z, Miao J, Wang L, LiuY, Ji H, Zhang X, et al. EGFR-mutant NSCLC presenting with stroke and massive systemic embolization as the first manifestation: case report. BMC Neurol 2021; 21: 221.
20. Naito H, Nezu T, Hosomi N, Aoki S, Ueno H, Ochi K, et al. Antithrombotic therapy strategy for cancer-associated ischemic stroke: a case series of 26 patients. J Stroke Cerebrovasc Dis 2018; 27: e206-e211.
21. Nonagase Y, Takeda M, Tanaka K, Hayashi H, Iwasa T, Nakagawa K. Treatment of EGFR mutation-positive non-small cell lung cancer complicated by Trousseau syndrome with gefitinib followed by osimertinib: a case report. Oncotarget 2018; 9: 29532-29535.
22. Kai Y, Ohara H, Matsuda M, Shimizu H, Park HS, Myouchin K, et al. Endovascular therapy for cerebral infarction due to Trousseau syndrome in a patient with non-small cell lung cancer. Respir Med Case Rep 2021; 34: 101531.
23. Tai ML, Tan EC, Ang CC, Liam CK. Recurrent cerebral infarcts secondary to marantic endocarditis in a patient with adenocarcinoma of the lung. Singapore Med J 2016; 57: 524-525.
24. Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WEE, et al, International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions, International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee Advisory Boards and Participating Institutions The IASLC lung cancer staging project: Proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 2016; 11: 39-51.
25. Batra U, Biswas B, Prabhash K, Krishna MV. Differential clinicopathological features, treatments and outcomes in patients with Exon 19 deletion and Exon 21 L858R EGFR mutation-positive adenocarcinoma non-small-cell lung cancer. BMJ Open Respir Res 2023; 10: e001492.
26. Akinbo DB, Ajayi OI. Thrombotic pathogenesis and laboratory diagnosis in cancer patients, an update. Int J Gen Med 2023; 16: 259-272.
27. Kono T, Ohtsuki T, Hosomi N, Takeda I, Aoki S, Sueda Y, et al. Cancer- ssociated ischemic stroke is associated with elevated D-dimer and fibrin degradation product levels in acute ischemic stroke with advanced cancer. Geriatr Gerontol Int 2012; 12: 468-474.
28. Grazioli S, Paciaroni M, Agnelli G, Acciarresi M, Alberti A, D’Amo- re C, et al. Cancer-associated ischemic stroke: a retrospective multicentre cohort study. Thromb Res 2018; 165: 33-37.
29. Zhang ZM, Lin ZH, Zhu G. Tirofiban in the treatment of cancer-associated ischemic stroke. Eur Rev Med Pharmacol Sci 2023; 27: 3590-3596.
30. Yang Y, Zhou Z, Niu XM, Li ZM, Chen ZW, Jian H, et al. Clinical analysis of postoperative venous thromboembolism risk factors in lung cancer patients. J Surg Oncol 2012; 106: 736-741.
31. Lee YG, Kim I, Lee E, Bang SM, Kang CH, Kim YT, et al. Risk factors and prognostic impact of venous thromboembolism in Asian patients with non-small cell lung cancer. Thromb Haemost 2014; 111: 1112-11120.
32. Corrales-Rodriguez L, Soulières D, Weng X, Tehfe M, Florescu M, Blais N. Mutations in NSCLC and their link with lung cancer- associated thrombosis: a case-control study. Thromb Res 2014; 133: 48-51.
33. Verso M, Chiari R, Mosca S, Franco L, Fischer M, Paglialunga L, et al. Incidence of Ct scan-detected pulmonary embolism in patients with oncogene-addicted, advanced lung adenocarcinoma. Thromb Res 2015; 136: 924-927.
34. Davidsson E, Murgia N, Ortiz-Villalón C, Wiklundh E, Sköld M, Kölbeck KG, et al. Mutational status predicts the risk of thromboembolic events in lung adenocarcinoma. Multidiscip Respir Med 2017; 12: 16.
35. Dou F, Li H, Zhu M, Liang L ZhangY, Yi J, et al. Association between oncogenic status and risk of venous thromboembolism in patients with non-small cell lung cancer. Respir Res 2018; 19: 88.
36. Wang J, Hu B, Li T, Miao J, Zhang W, Chen S, et al. The EGFR-rearranged adenocarcinoma is associated with a high rate of venous thromboembolism. Ann Transl Med 2019; 7: 724.
37. Dunbar A, Bolton KL, Devlin SM, Sanchez-Vega F, Gao J, Mones JV, et al. Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors. Blood 2021; 137: 2103-2113.
38. Feldman S, Gupta D, Navi BB, Grace Ho KW, Willeit P, Devlin S, et al. Tumor genomic profile is associated with arterial thromboembolism risk in patients with solid cancer. JACC Cardio Oncol 2023; 5: 246-255.
39. Roopkumar J, Poudel SK, Gervaso L, Reddy CA, Velcheti V, Pen- nell NA, et al. Risk of thromboembolism in patients with ALK- and EGFR-mutant lung cancer: a cohort study. J Thromb Haemost 2021; 19: 822-829.
40. Ueland T, Åkerblom A, Ghukasyan T, Michelsen AE, Becker RC, Bertilsson M, et al. Admission levels of DKK1 (Dickkopf-1) are associated with future cardiovascular death in patients with acute coronary syndromes. Arterioscler Thromb Vasc Biol 2019: 39: 294-302.
41. Hudy D, Gaździcka J, Świętek A, Gołąbek K, Rydel M, Czyżewski D, et al. The assessment of Dickkopf-1 and Dickkopf-2 protein concentration in different subtypes of non-small cell lung cancer subtypes. Contemp Oncol 2024; 28: 9-14.
42. Yannoutsos A, Cacciatore C, Jaouen S, Farge D, Frere C. Treatment of cancer-associated venous thromboembolism: A focus on special populations. J Med Vasc 2023; 48: 124-135.
43. Napolitano M, Siragusa S. The role of injectables in the treatment and prevention of cancer-associated thrombosis. Cancers (Basel) 2023; 15: 4640.
44. Gervaso L, Dave H, Khorana AA. Venous and arterial thromboembolism in patients with cancer: JACC: CardioOncology State-of-the-Art Review. JACC Cardio Oncol 2021; 3: 173-190.
45. Maezawa Y, Taguchi M, Kawakami T, Inui T, Okauchi S, Numa- ta T, et al. Age and smoking intensity in non-small cell lung cancer patients with the anaplastic lymphoma kinase fusion gene. Contemp Oncol 2025; 29: 93-98.
Copyright: © 2025 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.